ClinicalTrials.gg
RecruitingNCT07663838Updated Oct 15, 2026

A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)

A Phase 1 interventional study of GenSci142 capsule and clindamycin phosphate vaginal cream in Randomized, Open-label and Safety, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Recruiting at 9 sites in China. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 15, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 16 studies in Vaginosis, Bacterial with a site in China — 6 open to participants now, 6 under way, none of them phase 3. Vaginosis, Bacterial · China.

Planned enrollment
15th of 16
42 · median 123
Started
2026
with 2 others
Phase 1
3 of 16
2 open now
Registered
15th of 16
by date
Lead sponsor
2 of 16
Changchun GeneScience Pharmaceutical Co., Ltd.

Among the 16 studies in Vaginosis, Bacterial with a site in China, this one is the 15th largest by planned enrollment, is one of 3 that started in 2026, is one of 3 in phase 1, and was the 15th registered.

Vaginosis, Bacterial

240 studies on the registry are indexed under Vaginosis, Bacterial; 39 are open to participants now.

Browse Vaginosis, Bacterial studies →

Open to participants now

6 of the 16 studies in Vaginosis, Bacterial with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 23 Vaginosis, Bacterial studies recruiting now, 7 (30%) set no upper age limit and 16 (70%) stop at 75 or younger; 2 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Vaginosis, Bacterial with a site in China, or all of them as a file.
02

Study summary

A randomized, multicenter, open-label, active-controlled Phase Ib study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of multiple intravaginal doses of GenSci142 in patients with bacterial vaginosis (BV).

Read the detailed description

This study aims to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of multiple intravaginal doses of GenSci142 in patients with bacterial vaginosis (BV) or BV combined mild aerobic vaginitis aged 18 to 50 years, providing a basis for subsequent clinical development. This is a randomized, multicenter, open-label, active-controlled clinical trial. A total of approximately 30 to 42 subjects are planned for enrollment and will be randomized in a 2:1 ratio to either the treatment group or the control group. Treatment group: GenSci142,.Control group: 2% clindamycin phosphate vaginal cream (referred to as clindamycin cream),.The study consists of a screening period (approximately 3 days), a treatment period (7 days), and a efficacy evaluation period (approximately 90 days), with a total of 7 scheduled visits.

03

Conditions studied

  • Randomized
  • Open-label
  • Safety
  • Tolerability
  • Pharmacokinetics
  • Bacterial Vaginosis

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 15, 2026. See what changed

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women of childbearing age aged 18-50 years (inclusive of the cut-off values, as of the date of signing the form), with a history of sexual activity and a regular menstrual cycle (21-35 days, inclusive of the cut-off values);
  2. Screening visits were conducted for women clinically diagnosed with bacterial vaginosis (BV) who had not received any treatment for BV since the onset of their current symptoms. The clinical diagnostic criteria for BV are as follows:

    1. At least one clinical symptom (itching, odour, abnormal vaginal discharge),
    2. and at least three positive findings on the Amsel clinical assessment (positivity for clue cells is a mandatory criterion),
    3. and a Nugent score of ≥7;
  3. Trial participants must agree to abstain from sexual intercourse for 48 hours prior to the first administration of the medicinal product, throughout the treatment period, and for 48 hours prior to each return visit;
  4. be willing to use vaginal administration and agree to avoid the use of any vaginal products not specified in the trial protocol (such as creams, gels, foams, sponges, lubricants, douches, tampons, etc.) throughout the trial period;
  5. Trial participants must voluntarily sign a written informed consent form prior to the trial;
  6. Trial participants must be able to understand the procedures and methods of this trial and be willing to strictly adhere to the clinical trial protocol to complete the trial.

Exclusion criteria

Exclusion Criteria:

Medical History

  1. Those currently suffering from any acute infection of the urinary or reproductive system, including but not limited to pelvic inflammatory disease, cervicitis, endometritis, and adnexitis;
  2. Those currently suffering from vulvovaginitis caused by other pathogens, including but not limited to VVC, trichomoniasis, genital herpes, and genital warts (CA), and only moderate-to-severe AV (AV score ≥5 by vaginal microecology assessment) is excluded;
  3. Current presence of other vaginal or vulvar conditions, or being in the recovery phase following reproductive system surgery, where the investigator considers this to affect the trial evaluation;
  4. Patients currently receiving, or who will require during the trial, medications that reduce or antagonise oestrogen levels, such as gonadotropin-releasing hormone (GnRH) agonists, high-potency progestogens and combined oral (COCs);
  5. Patients with a history of or currently suffering from major diseases such as cardiovascular, hepatic, renal, pulmonary, gastrointestinal, neurological, metabolic, urogenital, endocrine or psychiatric disorders, where the investigator considers inclusion inappropriate;
  6. Women who are pregnant, breastfeeding, or have tested positive for pregnancy; or those planning to become pregnant during the trial; or those unable to use reliable contraception during the study;
  7. Individuals with impaired immunity or immune dysfunction, including but not limited to those currently undergoing treatment for malignant tumours, those with diseases, or those currently using ;
  8. Participants with abnormal uterine bleeding (AUB) in whom cannot be ruled out, or who require a transvaginal surgical procedure within 90 days.;
  9. Those who are menstruating at the time of the screening visit or who are expected to commence menstruation within 14 days;
  10. Participants who have received treatment with inhalational anaesthetics, antispasmodic anti-diarrhoeal agents, kaolin-containing anti-diarrhoeal agents, muscle relaxants, chloramphenicol or erythromycin, or opioid analgesics within 7 days prior to screening;
  11. Participants who had received treatment with topical or systemic broad-spectrum antibiotics (excluding nitroimidazole antibiotics that do not affect Lactobacillus) within 1 month prior to screening;
  12. Those who have undergone vaginal douching or other vaginal procedures involving antiseptic treatment within 1 month prior to screening;
  13. A history of severe allergy to the medicinal product, any of its , or vaginal effervescent preparations; or a predisposition to allergies (e.g. allergy to two or more medicines or foods); Diet and lifestyle
  14. Those with an average daily cigarette consumption of ≥5 cigarettes in the 30 days prior to screening;
  15. Those who have consumed more than 5 litres of beer, 600 ml of spirits with an alcohol content of 40%, or 2 litres of wine per week within the 6 months prior to screening; History of substance abuse or dependence
  16. History of substance abuse within the past year (e.g. cannabis, benzodiazepines, ketamine, morphine, cocaine, methamphetamine); Screening examinations
  17. Participants with abnormalities or vaginal mucosal lesions (e.g. mucosal oedema, congestion, ulcers, erosions) identified during the screening colposcopy, as judged by the investigator, which may affect drug administration;
  18. During the screening period, based on an assessment of medical history, vital signs, physical examination, clinical laboratory tests and ancillary investigations, the investigator considers the subject's general health status unsuitable for inclusion (see Section 10.2.2 for details regarding laboratory test exclusion criteria);
  19. Participants with positive results in infectious disease screening [ surface antigen (HBsAg), antibody (HCV-Ab), antibody (HIV-Ab), or positive syphilis serology]; Other
  20. Participants who have participated in other clinical trials of medicinal products or medical devices within the 3 months prior to screening and have used the investigational medicinal product or device; or who participated in a clinical study 3 months prior but are still within the follow-up period of that study or within 5 half-lives of the investigational medicinal product (whichever is longer) at the time of screening; The investigator considers that the trial participant has any other condition rendering them unsuitable for participation in the trial, or any other medical condition that may impair the participant's ability to tolerate the investigational medicinal product or to continue with the procedures specified in this study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    GenSci142 capsule

    Drug: GenSci142 capsule

  • Active comparator
    clindamycin phosphate vaginal cream

    Drug: clindamycin phosphate vaginal cream

Interventions

  • DrugGenSci142 capsule

    Vaginal administration

  • Drugclindamycin phosphate vaginal cream

    Clindamycin ointment, 5 grams, once daily for 7 days

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment-emergent adverse events

    Time frame: From the first dose to Day 30

Secondary outcomes

  1. Clinical cure rate base on Amsel assessment

    Time frame: from first dose of study treatment up to 21~30 days after first dose

  2. Change of Nugent score from baseline

    Time frame: from first dose of study treatment up to 2 days after first dose

  3. Microbiological cure rate base on Nugent score of <4

    Time frame: from first dose of study treatment up to 21~30 days after first dose

  4. Clinical cure rate base on Amsel assessment

    Time frame: from first dose of study treatment up to 8~14 days after first dose

  5. Microbiological cure rate base on Nugent score of <4

    Time frame: from first dose of study treatment up to 8~14 days after first dose

  6. Rrecurrence rate (recurrence as assessed by either Amsel or Nugent score)

    Time frame: from first dose of study treatment up to 90 days after first dose

  7. Clinical recurrence rate base on Amsel assessment

    Time frame: from first dose of study treatment up to 90 days after first dose

  8. Microbiological recurrence rate base on score of >7

    Time frame: from first dose of study treatment up to 90 days after first dose

  9. Time to clinical symptoms disappear

    Time frame: from first dose of study treatment up to 30 days

  10. Time to recurrence

    Time frame: from first dose of study treatment up to 90 days after first dose

  11. Concentrations of GenSci142 in serum samples at different time points are measured. Serum concentrations at different time points will be listed and summarized by descriptive statistics.

    Only for GenSci142 dose group

    Time frame: from pre-dose up to 2 days after first dose

  12. Anti-drug antibody prevalence (%) or change of binding titers against GenSci142 in blood before administration and at the follow-up visit

    For each group

    Time frame: from pre-dose up to 90 days after first dose

07

Study locations

9 of 9 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Aug 2026 (actual). Primary completion is estimated for Jan 2027, 4 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Aug 2026, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2026
First posted
Jun 23, 2026
StartActual
Aug 15, 2026was Jun 2026
Primary completionEst.
Jan 5, 2027
CompletionEst.
May 5, 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 15, 2026
Sites
2 sites added. 7 sites changed recruiting status (7 now recruiting)
Show 7 sites
  • Beijing Tsinghua Changgung Hospital · Beijing, Chinano status→Recruiting
  • Nanjing Maternity and Child Health Care Hospital · Nanjing, Chinano status→Recruiting
  • Jiangxi Provincial Women and Children's Medical Center · Nanchang, Chinano status→Recruiting
  • The First Hospital of Jilin University · Changchun, Chinano status→Recruiting
  • Shandong Provincial Hospital · Jinan, Chinano status→Recruiting
  • The Second Hospital of Shanxi Medical University · Taiyuan, Chinano status→Recruiting
  • Tianjin Medical University General Hospital · Tianjin, Chinano status→Recruiting
Show 2 added (2 China)
  • The first Affiliated hospital of Henan Medical University · Xinxiang, China
  • Affiliated Hangzhou First People's hospital · Hangzhou, China
Oct 15, 2026
Start date
Jun 15, 2026→Aug 15, 2026 (actual)
Oct 15, 2026
Enrollment
30→42
Oct 15, 2026
Eligibility
2 inclusion criteria edited; 6 exclusion criteria edited, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedScreening visits were conducted for women clinically diagnosed with bacterial vaginosis (BV) who had not received any treatment for bacterial vaginosisBV since the onset of their current symptoms. The clinical diagnostic criteria for bacterial vaginosisBV are as follows:
  • Editedand at least three positive findings on the Amsel clinical assessment (withpositivity for clue cells constituting more than 20% of the total vaginal epithelial cells beingis a mandatory criterion),
Exclusion criteria
  • EditedThose currently suffering from vulvovaginitis caused by other pathogens, including but not limited to Aerobic vaginitis, vulvovaginal candidiasisVVC, trichomoniasis, gonorrhoea, genital herpes, and genital warts (CA), and only moderate-to-severe AV (AV score ≥5 by vaginal microecology assessment) is excluded;
  • EditedPatients currently receiving, or who will require during the trial, medications that reduce or antagonise oestrogen levels, such as gonadotropin-releasing hormoneagonistshormone (GnRH) agonists, high-potency progestogens and combined oral contraceptives (COCs);
  • ChangedBefore Participants with abnormal uterine bleeding, including prolonged menstrual periods (>7 days);Now Participants with abnormal uterine bleeding (AUB) in whom malignancy cannot be ruled out, or who require a transvaginal surgical procedure within 90 days.;
  • EditedDuring the screening period, based on an assessment of medical history, vital signs, physical examination, clinical laboratory tests and ancillary investigations, the investigator considers the subject's general health status unsuitable for inclusion (see Section 10.2.2 for details regarding laboratory test exclusion criteria);
  • EditedParticipants with positive results in infectious disease screening [Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV-Ab), Human Immunodeficiency Virus antibody (HIV-Ab), or positive syphilis serology]; Other
  • EditedParticipants who have participated in other clinical trials of medicinal products or medical devices within the 3 months prior to screening and have used the investigational medicinal product or device; or who participated in a clinical study 3 months prior but are still within the follow-up period of that study or within 5 half-lives of the investigational medicinal product (whichever is longer) at the time of screening; The investigator considers that the trial participant has any other condition rendering them unsuitable for participation in the trial, or any other medical condition that may impair the participant's ability to tolerate the investigational medicinal product or to continue with the procedures specified in this study.
  • RemovedThe investigator considers that the trial participant has any other condition rendering them unsuitable for participation in the trial, or any other medical condition that may impair the participant's ability to tolerate the investigational medicinal product or to continue with the procedures specified in this study.
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Not yet recruiting→Recruiting
    2 sites added. 7 sites changed recruiting status (7 now recruiting)
    Show 7 sites
    • Beijing Tsinghua Changgung Hospital · Beijing, Chinano status→Recruiting
    • Nanjing Maternity and Child Health Care Hospital · Nanjing, Chinano status→Recruiting
    • Jiangxi Provincial Women and Children's Medical Center · Nanchang, Chinano status→Recruiting
    • The First Hospital of Jilin University · Changchun, Chinano status→Recruiting
    • Shandong Provincial Hospital · Jinan, Chinano status→Recruiting
    • The Second Hospital of Shanxi Medical University · Taiyuan, Chinano status→Recruiting
    • Tianjin Medical University General Hospital · Tianjin, Chinano status→Recruiting
    Show 2 added (2 China)
    • The first Affiliated hospital of Henan Medical University · Xinxiang, China
    • Affiliated Hangzhou First People's hospital · Hangzhou, China
    Start date Jun 15, 2026→Aug 15, 2026 (now actual)
    Enrollment 30→42
    Eligibility 2 inclusion criteria edited; 6 exclusion criteria edited, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedScreening visits were conducted for women clinically diagnosed with bacterial vaginosis (BV) who had not received any treatment for bacterial vaginosisBV since the onset of their current symptoms. The clinical diagnostic criteria for bacterial vaginosisBV are as follows:
    • Editedand at least three positive findings on the Amsel clinical assessment (withpositivity for clue cells constituting more than 20% of the total vaginal epithelial cells beingis a mandatory criterion),
    Exclusion criteria
    • EditedThose currently suffering from vulvovaginitis caused by other pathogens, including but not limited to Aerobic vaginitis, vulvovaginal candidiasisVVC, trichomoniasis, gonorrhoea, genital herpes, and genital warts (CA), and only moderate-to-severe AV (AV score ≥5 by vaginal microecology assessment) is excluded;
    • EditedPatients currently receiving, or who will require during the trial, medications that reduce or antagonise oestrogen levels, such as gonadotropin-releasing hormoneagonistshormone (GnRH) agonists, high-potency progestogens and combined oral contraceptives (COCs);
    • ChangedBefore Participants with abnormal uterine bleeding, including prolonged menstrual periods (>7 days);Now Participants with abnormal uterine bleeding (AUB) in whom malignancy cannot be ruled out, or who require a transvaginal surgical procedure within 90 days.;
    • EditedDuring the screening period, based on an assessment of medical history, vital signs, physical examination, clinical laboratory tests and ancillary investigations, the investigator considers the subject's general health status unsuitable for inclusion (see Section 10.2.2 for details regarding laboratory test exclusion criteria);
    • EditedParticipants with positive results in infectious disease screening [Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV-Ab), Human Immunodeficiency Virus antibody (HIV-Ab), or positive syphilis serology]; Other
    • EditedParticipants who have participated in other clinical trials of medicinal products or medical devices within the 3 months prior to screening and have used the investigational medicinal product or device; or who participated in a clinical study 3 months prior but are still within the follow-up period of that study or within 5 half-lives of the investigational medicinal product (whichever is longer) at the time of screening; The investigator considers that the trial participant has any other condition rendering them unsuitable for participation in the trial, or any other medical condition that may impair the participant's ability to tolerate the investigational medicinal product or to continue with the procedures specified in this study.
    • RemovedThe investigator considers that the trial participant has any other condition rendering them unsuitable for participation in the trial, or any other medical condition that may impair the participant's ability to tolerate the investigational medicinal product or to continue with the procedures specified in this study.
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07663838
Responsible party
Sponsor
First posted
Jun 23, 2026
Start date
Aug 15, 2026
Primary completion
Jan 5, 2027 (estimated)
Completion
May 5, 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Liao Qinping
Contact
13701124527@163.com
+86 13701124527
Zhang Lei
Contact
18601130459@163.com
+86 18601130459

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion